With 0.57 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.15 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $13.57 whereas the lowest price it dropped to was $11.0. The 52-week range on JBIO shows that it touched its highest point at $13.50 and its lowest point at $6.57 during that stretch. It currently has a 1-year price target of $19.80. Beta for the stock currently stands at 0.89.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of JBIO was up-trending over the past week, with a rise of 35.67%, but this was up by 34.36% over a month. Three-month performance surged to 71.06% while six-month performance rose 69.68%. The stock gained 29.92% in the past year, while it has gained 30.91% so far this year. A look at the trailing 12-month EPS for JBIO yields -11.36 with Next year EPS estimates of -1.94. For the next quarter, that number is -0.48. This implies an EPS growth rate of 95.86% for this year and 34.46% for next year. EPS is expected to grow by 66.72% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of -77.98%.
Float and Shares Shorts:
At present, 32.63 million JBIO shares are outstanding with a float of 24.29 million shares on hand for trading. On 2025-10-31, short shares totaled 1.03 million, which was 223.99999999999997 higher than short shares on 1759190400. In addition to Mr. Tom Frohlich as the firm’s CEO & Director, Mr. Bradford D. Dahms Ph.D. serves as its Chief Financial Officer.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2025-09-30, JBIO reported revenue of $0.0 and operating income of -$27778000.0. The EBITDA in the recently reported quarter was -$27778000.0 and diluted EPS was -$0.86.
Analysts Ratings:
In the same way, a target price assigned to a stock can also reveal much about its potential. With JBIO analysts setting a high price target of 28.0 and a low target of 14.0, the average target price over the next 12 months is 19.2. Based on these targets, JBIO could surge 122.4% to reach the target high and rise by 11.2% to reach the target low. Reaching the average price target will result in a growth of 52.5% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of -$85.2635 being high and -$85.2635 being low. For JBIO, this leads to a yearly average estimate of -$85.2635. Based on analyst estimates, the high estimate for the next quarter is -$0.3 and the low estimate is -$0.57. The average estimate for the next quarter is thus -$0.47.
